Hydronidone
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Hydronidone
- Molecular weight
- 201.22
- Structure (SMILES)
- Cc1ccc(=O)n(-c2ccc(O)cc2)c1
- f 351
- F 351
- F-351
- hydronidone
- Hydronidone
- Hydronidone (270mg)
- Hydronidone capsules
- Hydronidone Capsules
- CAS registry numbers
- 851518-71-3
- ChEMBL ID
- CHEMBL4297288
- InChIKey
- NETTXQJYJRFTFS-UHFFFAOYSA-N
- PubChem compound IDs
- 11217901
- FDA ingredient codes (UNII)
- RXQ128313W
- First in class
- No
- Orphan designation
- No
- Condition
- Liver Cirrhosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001422
- Subject identifier
- D008103
- Condition
- Hepatitis B, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004239
- Subject identifier
- D019694
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- HP:0001410
- Subject identifier
- D008107
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001422
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004239
- Highest recorded phase
- 2
- Condition identifier
- HP_0001395
- Highest recorded phase
- 1
- Condition identifier
- HP_0001395
- Highest recorded phase
- 3
- Condition identifier
- HP_0001410
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005154
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005155
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005366
- Highest recorded phase
- 3
- NCT02499562
- NCT04123769
- NCT05115942
- NCT05905172
- Hydrogen bond acceptors
- 3
- Hydrogen bond donors
- 1
- Polar surface area
- 42.23
- Calculated partition coefficient (ALogP)
- 1.85
- Calculated partition coefficient (XLogP)
- 1.5
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 15
- Molecular formula
- C12H11NO2
- Monoisotopic mass
- 201.078978594
- Natural product
- No
- Recorded assays
- 6
- Active assays
- 0
Related records
Trials (16)
- [¹⁴C] Hydronidone Mass Balance Study
- A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
- A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis
- A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
- A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis
- A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
- A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
- Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
- Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
- Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects
- QTc Assessment in a Single-Dose Study of Hydronidone Capsules
- Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
- Study on Hydronidone Capsule BE
- Study on Pharmacokinetics of Hydronidone
- Study on PK of Hydronidone in Patients and Special Population
- The Phase Ⅰd Clinical Trial of Hydronidone Capsules
In development for (4)
- Chronic hepatitis B virus infection Phase 2
- Chronic kidney disease Phase 1
- Cirrhosis of liver Phase 3
- Liver disorder Phase 1